---
schema_version: "secwatch.filing_event.v1"
accession: "0001390478-24-000016"
form_type: "8-K"
ticker: "SLS"
cik: "0001390478"
company_name: "SELLAS Life Sciences Group, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:38:50.368581+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# SELLAS Life Sciences Q2 2024 net loss $7.5M; cash $9.1M; $21M capital raise; IDMC supports REGAL

## Summary
- Net loss $7.5M ($0.13/share) vs $8.8M ($0.31/share) in Q2 2023; R&D expenses $5.2M.
- Cash $9.1M at June 30; subsequent $21M gross proceeds from premium-priced registered direct offering.
- IDMC recommends continue Phase 3 REGAL (GPS) in AML without modifications; interim analysis expected by Q4 2024.
- Phase 2a SLS009 in r/r AML: ORR 33% (60mg QW), 50% (30mg BIW), 100% in ASXL1 mutant cohort.

## SEC filing metadata
- accession: 0001390478-24-000016
- form_type: 8-K
- ticker: SLS
- cik: 0001390478
- company_name: SELLAS Life Sciences Group, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000139047824000016/0001390478-24-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1390478/000139047824000016/sls-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001390478-24-000016
- JSON: https://secwatch.observer/filing/0001390478-24-000016.json
- Plain text: https://secwatch.observer/filing/0001390478-24-000016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.